Actively Recruiting
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
Led by Qilu Hospital of Shandong University · Updated on 2026-03-24
60
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Narcolepsy (NRL) is a rare chronic central nervous system dysfunction disease, which is more common in children and adolescents, and less common in adults. Its typical clinical features include excessive daytime sleep, paroxysmal cataplexy, sleep paralysis and sleep hallucination. In addition to the above typical manifestations, patients with narcolepsy can also manifest as hyperappetite, weight gain, multiple dreams, sleep fragmentation, anxiety and depression and other emotional disorders. In particular, in narcolepsy type 1 with cataplexy, cataplexy episodes can be confused with falls caused by seizures, transient ischemic attacks or neuromuscular disorders, or even mental conversion disorders. Due to its diverse clinical symptoms, it is easy to be missed and misdiagnosed. At present, the pathogenesis of narcolepsy is still unclear, and its pathogenesis may be related to immune, genetic, environmental, infection, central nervous system degeneration and other factors. This study aims to investigate the changes of body fluid proteomics and metabolomics in patients with narcolepsy, and to provide an important basis for the pathogenesis of narcolepsy.
CONDITIONS
Official Title
Proteomics and Metabolomics of Body Fluid in Patients With Narcolepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must meet the diagnostic criteria of the International Classification of Sleep Disorders, Third edition (ICSD-3).
You will not qualify if you...
- Primary hypersomnia or hypersomnia due to shift work, sleep deprivation, or other sleep rhythm disturbances.
- Excessive sleep caused by drug abuse.
- Diagnosis of Parkinson's disease, Alzheimer's disease, other nervous system diseases, or mental illnesses.
- Presence of heart, lung, liver, kidney, blood, endocrine system diseases, or recent acute or chronic infections.
- Use of sedatives, hypnotics, antidepressants, lithium, or dopamine receptor antagonists within two weeks before examination.
- Inability to cooperate with polysomnography (PSG) and multiple sleep latency test (MSLT).
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012
Actively Recruiting
Research Team
H
haiyun li
CONTACT
W
wenjing jiang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here